BREAST CANCER Despite preclinical data identifying oncogenic RANK pathway activation, the RANK ligand inhibitor denosumab failed to improve outcomes in the neoadjuvant or adjuvant settings

by OncoDNA

Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Investigadores cordobeses participan en ...

by Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

Investigadores del grupo Hormonas y Cáncer del IMIBIC, la Universidad...

Photos Stream